| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -7.0 | -6.0 |
| EPS (diluted, $ a share) | $-0.25 | $-0.33 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: UNCY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Unicycive Therapeutics, Inc.: key numbers
- Share price
- $3.70Close, Nov 17
- Market cap
- $108M
- Shares outstanding
- 29.18MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Unicycive Therapeutics, Inc.
All →Unicycive Therapeutics Financial Results
Unicycive Therapeutics reported third quarter 2026 financial results and provided a business update regarding its New Drug Application (NDA) for oxylanthanum carbonate (OLC). The FDA has accepted the NDA resubmission with a PDUFA target action date of March 25, 2027, following a previous Complete Response Letter related to manufacturing vendor deficiencies.
“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients. With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch.”
Shalabh Gupta, M.D., Chief Executive Officer
Unicycive Therapeutics Leadership Change
Unicycive Therapeutics appointed Meredith S. Manning as an independent director to its board, effective October 1, 2026. Ms. Manning, who previously served as Chief Commercial Officer of Soleno Therapeutics, will also serve as Chairperson of the Nominating and Corporate Governance Committee. The company also announced the resubmission of its New Drug Application for Oxylanthanum Carbonate with a new manufacturing vendor.
- Counterparty
- Meredith S. Manning
Unicycive Therapeutics Court & Legal Update
A securities class action lawsuit has been filed against Unicycive Therapeutics and certain officers in the U.S. District Court for the Northern District of California. The lawsuit alleges violations of federal securities laws regarding public statements about the company's New Drug Application for oxylanthanum carbonate. Unicycive stated it believes the claims are meritless and intends to vigorously defend the action.